Search Results - "Sanjuan, X."

Prediction of pathological response to neoadjuvant treatment in rectal cancer with a two-protein immunohistochemical score derived from stromal gene-profiling by Gonçalves-Ribeiro, S., Sanz-Pamplona, R., Vidal, A., Sanjuan, X., Guillen Díaz-Maroto, N., Soriano, A., Guardiola, J., Albert, N., Martínez-Villacampa, M., López, I., Santos, C., Serra-Musach, J., Salazar, R., Capellà, G., Villanueva, A., Molleví, D.G.

“…Preoperative chemoradiotherapy followed by surgical mesorectal resection is the standard of care for locally advanced rectal carcinomas. Yet, predicting that…”
Get full text

Improving survival and local control in rectal cancer in Catalonia (Spain) in the context of centralisation: A full cycle audit assessment by Manchon-Walsh, P, Aliste, L, Espinàs, J.A, Prades, J, Guarga, A, Balart, J, Biondo, S, Castells, A, Sanjuan, X, Tabernero, J, Borras, J.M

“…Abstract Background Rectal cancer surgery in Catalonia has been involved in a process of centralisation. We assessed the impact of this health policy strategy…”
Get full text

KRAS mutations as a prognostic factor after metastasectomy in colorectal cancer patients by Domenech Viñolas, M, Santos, C, Pérez, J, Varela, M, Martinez Villacampa, M, Teule, A, Ruffinelli Rodriguez, J C, Mulet Margalef, N, Soler, G, Ortega, A, Bergamino, M S, SanJuan, X, Torras, J, Ramos, E, Salazar, R

Get full text

P-160Impact of KRAS mutation on patterns of metastasis in a series of colorectal cancer patients by Domenech Vinolas, M, Santos, C, Perez Martin Francisco, J, Varela, M, Merche, M, Grasselli, J, Teule, A, Soler, G, Mulet Margalef, N, Bergamino Sirven, M, Ortega Franco, A, Sanjuan, X, Salazar, R

Get full text

Clinicopathological risk factors of Stage II colon cancer: results of a prospective study by Santos, C., López-Doriga, A., Navarro, M., Mateo, J., Biondo, S., Martínez Villacampa, M., Soler, G., Sanjuan, X., Paules, M. J., Laquente, B., Guinó, E., Kreisler, E., Frago, R., Germà, J. R., Moreno, V., Salazar, R.

“…Aim  Adjuvant 5‐fluorouracil based chemotherapy has demonstrated benefit in Stage III colon cancer but still remains controversial in Stage II. The aim of this…”
Get full text

Differential expression of galectin 3 and galectin 1 in colorectal cancer progression by Sanjuan, X, Fernandez, PL, Castells, A, Castronovo, V, van den Brule, F, Liu, FT, Cardesa, A, Campo, E

“…BACKGROUND & AIMS: Galectins are beta-galactoside-binding proteins possibly involved in tumor progression. The aim of this study was to determine the pattern…”
Get full text

478P TA-ness classification discriminates RAS wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts) who may benefit from antiEGFR treatment by Santos, C., Lawrence, P., Lopez-Doriga, A., Ragulan, C., Fontana, E., Desai, K., Ps, H., Elez Fernandez, M.E., Aranda Aguilar, E., Losa, F., Paez, D., Layos Romero, L., Sanjuan, X., Cañas, M.A., Azuara, D., Queralt, B., Fernandez-Calotti, P., Salazar, R., Sadanandam, A.

Get full text

512PKRAS mutations as a prognostic factor after metastasectomy in colorectal cancer patients by Domenech Viñolas, M, Santos, C, Pérez, J, Varela, M, Martinez Villacampa, M, Teule, A, Ruffinelli Rodriguez, J C, Mulet Margalef, N, Soler, G, Ortega, A, Bergamino, M S, SanJuan, X, Torras, J, Ramos, E, Salazar, R

Get full text

Identification of a Twelve-microRNA Signature with Prognostic Value in Stage II Microsatellite Stable Colon Cancer by Moratalla-Navarro, Ferran, Díez-Villanueva, Anna, Garcia-Serrano, Ainhoa, Closa, Adrià, Cordero, David, Solé, Xavier, Guinó, Elisabet, Sanz-Pamplona, Rebeca, Sanjuan, Xavier, Santos, Cristina, Biondo, Sebastiano, Salazar, Ramón, Moreno, Victor

“…We aimed to identify and validate a set of miRNAs that could serve as a prognostic signature useful to determine the recurrence risk for patients with COAD…”
Get full text

P-195 SPRY2 and response to FOLFOX/CAPOX in metastatic KRAS mutated colorectal cancer by Montal, R., Merche, M.-V., Anta, B., Martínez, N., Santos, C., Sanjuan, X., Paúles, M.J., Pérez Martín, F.J., Azuara, D., Salazar, R., Rojas, J.M.

Get full text

P-160 Impact of KRAS mutation on patterns of metastasis in a series of colorectal cancer patients by Domenech Viñolas, M., Santos, C., Pérez Martín Francisco, J., Varela, M., Merche, M., Grasselli, J., Teule, A., Soler, G., Mulet Margalef, N., Bergamino Sirven, M., Ortega Franco, A., Sanjuan, X., Salazar, R.

Get full text

Extended genotyping of RAS/BRAF for improved selection of metastatic CRC patients to anti-EGFR therapy: Comparison of three platforms by Azuara, D., Garcia-Carbonero, R., Alfonso, P. García, Santos-Vivas, C., Navarro, V., Varela, M., Carrato, A., Elez, E., Cano, M.T., Losa, F., Montagut, C., Sureda, B. Massuti, Manzano, J.L., Vieitez, J., Valladares-Ayerbes, M., Sanjuan, X., Capellá, G., Tabernero, J., Aranda, E., Salazar, R.

Get full text

GALECTIN-3 AND LAMININ EXPRESSION IN NEOPLASTIC AND NON-NEOPLASTIC THYROID TISSUE by FERNÁNDEZ, PEDRO L., MERINO, MARÍA J., GÓMEZ, MERCEDES, CAMPO, ELÍAS, MEDINA, TERESA, CASTRONOVO, VINCENT, SANJUÁN, XAVIER, CARDESA, ANTONIO, LIU, FU-TONG, SOBEL, MARK E.

“…Galectin‐3 is a 31 kD β‐galactoside‐binding lectin which is expressed by several types of non‐neoplastic and neoplastic cells and which may be involved in…”
Get full text

O-012 Nanofluidic digital PCR and extended genotyping of RAS, BRAF and PI3KCA for improved selection of metastatic colorectal cancer patients to anti-EGFR therapies by Azuara, D., Santos, C., Lopez-Doriga, A., Grasselli, J., Nadal, M., Sanjuan, X., Marin, F., Morell, M., Montal, R., Moreno, V., Montagut, C., Bellosillo, B., Argiles, G., Elez, E., Tabernero, J., Capellá, G., Salazar, R.

Get full text

OVEREXPRESSION OF THE 67-kD LAMININ RECEPTOR CORRELATES WITH TUMOUR PROGRESSION IN HUMAN COLORECTAL CARCINOMA by SANJUÁN, XAVIER, FERNÁNDEZ, PEDRO L., MIQUEL, ROSA, MUÑOZ, JOSEP, CASTRONOVO, VINCENT, MÉNARD, SYLVIE, PALACÍN, ANTONIO, CARDESA, ANTONIO, CAMPO, ELÍAS

“…The high affinity 67‐kD laminin receptor (67LR) is a cell surface protein whose expression is increased in a number of human carcinoma models. To date, 67LR…”
Get full text

227PPROGNOSIS OF PHOSPHORYLATED-INSULIN GROWTH FACTOR RECEPTOR (P-IGF-1R) AND METALLOPROTEINASE-3 (MMP3) EXPRESSION IN ADVANCED GASTROINTESTINAL STROMAL TUMORS (GIST) PATIENTS TREATED WITH IMATINIB. A GEIS STUDY by Maurel, J., Lopez-Pousa, A., Calabuig, S., Bagué, S., Del Muro, X. García, Sanjuan, X., Rubió, J., Cuatrecasas, M., Martinez-Trufero, J., Horndler, C., Fra, J., Morales, C. Valverde, Redondo, A., Poveda, A.M., Sevilla, I., Lainez, N., Rubini, M., Albéniz, X. García, Broto, J. Martin, De Álava, E.

“…Abstract Aim: Most GISTs have mutations in KIT or PDGFRA. Patients with advanced GIST with KIT exon 9, with PDGFRA mutation or WT for KIT and PDGFRA have a…”
Get full text

Prognosis of Phosphorylated-Insulin Growth Factor Receptor (P-Igf-1R) and Metalloproteinase-3 (Mmp3) Expression in Advanced Gastrointestinal Stromal Tumors (Gist) Patients Treated with Imatinib. a Geis Study by Maurel, J., Lopez-Pousa, A., Calabuig, S., Bagué, S., Del Muro, X. García, Sanjuan, X., Rubió, J., Cuatrecasas, M., Martinez-Trufero, J., Horndler, C., Fra, J., Morales, C. Valverde, Redondo, A., Poveda, A.M., Sevilla, I., Lainez, N., Rubini, M., Albéniz, X. García, Broto, J. Martin, De Álava, E.

Get full text

1068PA PHASE 1 MECHANISM OF ACTION STUDY OF INTRA-TUMOURAL (IT) OR INTRAVENOUS (IV) ADMINISTRATION OF ENADENOTUCIREV, AN ONCOLYTIC AD11/AD3 CHIMERIC GROUP B ADENOVIRUS IN COLON CANCER PATIENTS UNDERGOING RESECTION OF PRIMARY TUMOUR by Boni, V., De La Portilla, F., Cubillo, A., Gil-Martin, M., Calvo, E., Salazar, R., Santos, C., Sanchez-Gastaldo, A., Prados, S., Sanjuan, X., Bozada, J.M., Duran, H., Jurado, M., Ellis, C., Alvis, S., Beadle, J., Fisher, K., Blanc, C., Garcia-Carbonero, R.

“…Abstract Aim: Enadenotucirev (EnAd) is a tumour selective chimeric Ad11/Ad3 group B adenovirus that has demonstrated preclinical activity in a model of…”
Get full text

A Phase 1 Mechanism of Action Study of Intra-Tumoural (It) or Intravenous (Iv) Administration of Enadenotucirev, an Oncolytic Ad11/Ad3 Chimeric Group B Adenovirus in Colon Cancer Patients Undergoing Resection of Primary Tumour by Boni, V., De La Portilla, F., Cubillo, A., Gil-Martin, M., Calvo, E., Salazar, R., Santos, C., Sanchez-Gastaldo, A., Prados, S., Sanjuan, X., Bozada, J.M., Duran, H., Jurado, M., Ellis, C., Alvis, S., Beadle, J., Fisher, K., Blanc, C., Garcia-Carbonero, R.

Get full text

Hepatic Carcinoma-associated fibroblasts promote an adaptative response in colorectal cancer cells that inhibit proliferation and apoptosis by Berdiel, M, Bohem, ME, Lopez-Doriga, A, Vidal, A, Salazar, R, Martinez-Iniesta, M, Santos, C, Sanjuan, X, Villanueva, A, Mollevi, D G

“…Carcinoma-associated fibroblasts (CAFs) are important contributors of microenvironment in determining the tumour's fate. This study aimed to compare the…”
Get full text